Top

Journal of Gastrointestinal Surgery

Published in:

01-10-2008 | ssat plenary presentation

Applying Proteomic-Based Biomarker Tools for the Accurate Diagnosis of Pancreatic Cancer

Authors: Kyoko Kojima, Senait Asmellash, Christopher A. Klug, William E. Grizzle, James A. Mobley, John D. Christein

Published in: Journal of Gastrointestinal Surgery | Issue 10/2008

Abstract

Background

The proteome varies with physiologic and disease states. Few studies have been reported that differentiate the proteome of those with pancreatic cancer.

Aim

To apply proteomic-based technologies to body fluids. To differentiate pancreatic neoplasia from nonneoplastic pancreatic disease.

Methods

Samples from 50 patients (15 healthy (H), 24 cancer (Ca), 11 chronic pancreatitis (CP)) were prospectively collected and underwent analysis. A high-throughput method, using high-affinity solid lipophilic extraction resins, enriched low molecular weight proteins for extraction with a high-speed 200-Hz matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-MS; Bruker Ultraflex III). Samples underwent software processing with FlexAnalysis, Clinprot, MatLab, and Statistica (baseline, align, and normalize spectra). Nonparametric pairwise statistics, multidimensional scaling, hierarchical analysis, and leave-one-out cross validation completed the analysis. Sensitivity (sn) and specificity (sp) of group comparisons were determined. Two top-down-directed protein identification approaches were combined with MALDI-MS and tandem mass spectrometry to fully characterize the most significant protein biomarker.

Results

Using eight serum features, we differentiated Ca from H (sn 88%, sp 93%), Ca from CP (sn 88%, sp 30%), and Ca from both H and CP combined (sn 88%, sp 66%). In addition, nine features obtained from urine differentiated Ca from both H and CP combined with high efficiency (sn 90%, sp 90%). Interestingly, the plasma samples (considered by the Human Proteome Organization to be the preferred biological fluid) did not show significant differences. Multidimensional scaling indicated that markers from both serum and urine led to a highly effective clinical indicator of each specific disease state.

Conclusions

The proteomic analysis of noninvasively acquired biological fluids provided a high level of predictability for diagnosing pancreatic cancer. While the proteomic analysis of serum was capable of screening individuals for pancreatic disease (i.e., CP and Ca vs. H), specific urine biomarkers further distinguished malignancy (Ca) from chronic inflammation (CP).

Lam YW, Mobley JA, Evans JE, Carmody JF, Ho SM. Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005;5:2927–2938. doi:10.1002/pmic.200401165.PubMedCrossRef

Mobley JA, Lam YW, Lau KM, Pais VM, L'Esperance JO, Steadman B et al. Monitoring the serological proteome: the latest modality in prostate cancer detection. J Urol 2004;172:331–337. doi:10.1097/01.ju.0000132355.97888.50.PubMedCrossRef

Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–577. doi:10.1016/S0140-6736(02)07746-2.PubMedCrossRef

Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296–304.PubMed

Won Y, Song HJ, Kang TW, Kim JJ, Han BD, Lee SW. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Proteomics 2003;3:2310–2316. doi:10.1002/pmic.200300590.PubMedCrossRef

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.PubMedCrossRef

Christein JD, Kendrick ML, Iqbal CW, Nagorney DM, Farnell MB. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005;9:922–927. doi:10.1016/j.gassur.2005.04.008.PubMedCrossRef

Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996;83:625–631. doi:10.1002/bjs.1800830512.PubMedCrossRef

Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248–257. discussion 257–260.PubMedCrossRef

10.

Hauskrecht M, Pelikan R, Malehorn DE, Bigbee WL, Lotze MT, Zeh HJ et al. Feature selection for classification of SELDI-TOF-MS proteomic profiles. Appl Bioinformatics 2005;4:227–246. doi:10.2165/00822942-200504040-00003.PubMedCrossRef

11.

Rosty C, Goggins M. Identification of differentially expressed proteins in pancreatic cancer using a global proteomic approach. Methods Mol Med. 2005;103:189–197.PubMed

12.

Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005;68:79–86. doi:10.1159/000084824.PubMedCrossRef

13.

Jin Y, Manabe T. Direct targeting of human plasma for matrix-assisted laser desorption/ionization and analysis of plasma proteins by time of flight-mass spectrometry. Electrophoresis 2005;26:2823–2834. doi:10.1002/elps.200410421.PubMedCrossRef

14.

Bower H, Shulman R, Herbert P, Ronan R, Wehrly K. The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. J Biol Chem 1974;249:4975–4984.

15.

Roghani A, Zannis VI. Mutagenesis of the glycosylation site of human ApoCIII. O-linked glycosylation is not required for ApoCIII secretion and lipid binding. J Biol Chem 1988;263:17925–17932.PubMed

16.

Chen J, Anderson M, Misek DE, Simeone DM, Lubman DM. Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry. J Chromatogr A 2007;1162:117–125. doi:10.1016/j.chroma.2007.03.096.PubMedCrossRef

Title: Applying Proteomic-Based Biomarker Tools for the Accurate Diagnosis of Pancreatic Cancer
Authors: Kyoko Kojima
Senait Asmellash
Christopher A. Klug
William E. Grizzle
James A. Mobley
John D. Christein
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 10/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-008-0632-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Applying Proteomic-Based Biomarker Tools for the Accurate Diagnosis of Pancreatic Cancer

Abstract

Background

Aim

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2008

Sodium-Coupled Transport of the Short Chain Fatty Acid Butyrate by SLC5A8 and Its Relevance to Colon Cancer

Re: An Antecolic Roux-En-Y Type Reconstruction Decreased Delayed Gastric Emptying After Pylorus-Preserving Pancreatoduodenectomy by Murakami et al.

Laparoscopy-Assisted Distal Gastrectomy for Gastric Cancer

VEGF Gene Therapy Augments Localized Angiogenesis and Promotes Anastomotic Wound Healing: A Pilot Study in a Clinically Relevant Animal Model

Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s Patients

An FDA Approved Neurokinin-1 Receptor Antagonist is Effective in Reducing Intraabdominal Adhesions when Administered Intraperitoneally, But Not Orally